Abstract
Calcineurin inhibitors are widely used as maintenance immunosuppressants in solid-organ transplantation to minimize the risk of allograft rejection. Although the use of these agents has transformed the outcomes for patient and graft survival, this has come at a cost, notably the well-known adverse events of nephrotoxicity and metabolic abnormalities, to name a few. Over the last decade, tremendous interest has also focused on the impact of these medications on the replication of hepatitis C virus (HCV), with cyclosporine in particular having a negative effect on viral replication in vitro. Although small retrospective studies suggested that there may be a beneficial effect with cyclosporine on the progression of recurrent HCV and response to interferon, these findings have not been validated in several well-designed randomized controlled trial studies. The authors will review the pharmacology and pharmacokinetics of these well-known drugs and discuss the impact of these medications on the natural history of HCV recurrence after liver transplantation.
| Original language | English |
|---|---|
| Pages (from-to) | 587-593 |
| Number of pages | 7 |
| Journal | Expert Review of Clinical Pharmacology |
| Volume | 5 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 2012 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation : Implications for clinical practice. / Garcia-Saenz-De-Sicilia, Mauricio; Mukherjee, Sandeep.
In: Expert Review of Clinical Pharmacology, Vol. 5, No. 5, 09.2012, p. 587-593.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation
T2 - Implications for clinical practice
AU - Garcia-Saenz-De-Sicilia, Mauricio
AU - Mukherjee, Sandeep
PY - 2012/9
Y1 - 2012/9
N2 - Calcineurin inhibitors are widely used as maintenance immunosuppressants in solid-organ transplantation to minimize the risk of allograft rejection. Although the use of these agents has transformed the outcomes for patient and graft survival, this has come at a cost, notably the well-known adverse events of nephrotoxicity and metabolic abnormalities, to name a few. Over the last decade, tremendous interest has also focused on the impact of these medications on the replication of hepatitis C virus (HCV), with cyclosporine in particular having a negative effect on viral replication in vitro. Although small retrospective studies suggested that there may be a beneficial effect with cyclosporine on the progression of recurrent HCV and response to interferon, these findings have not been validated in several well-designed randomized controlled trial studies. The authors will review the pharmacology and pharmacokinetics of these well-known drugs and discuss the impact of these medications on the natural history of HCV recurrence after liver transplantation.
AB - Calcineurin inhibitors are widely used as maintenance immunosuppressants in solid-organ transplantation to minimize the risk of allograft rejection. Although the use of these agents has transformed the outcomes for patient and graft survival, this has come at a cost, notably the well-known adverse events of nephrotoxicity and metabolic abnormalities, to name a few. Over the last decade, tremendous interest has also focused on the impact of these medications on the replication of hepatitis C virus (HCV), with cyclosporine in particular having a negative effect on viral replication in vitro. Although small retrospective studies suggested that there may be a beneficial effect with cyclosporine on the progression of recurrent HCV and response to interferon, these findings have not been validated in several well-designed randomized controlled trial studies. The authors will review the pharmacology and pharmacokinetics of these well-known drugs and discuss the impact of these medications on the natural history of HCV recurrence after liver transplantation.
UR - http://www.scopus.com/inward/record.url?scp=84868530390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868530390&partnerID=8YFLogxK
U2 - 10.1586/ecp.12.49
DO - 10.1586/ecp.12.49
M3 - Review article
VL - 5
SP - 587
EP - 593
JO - Expert Review of Clinical Pharmacology
JF - Expert Review of Clinical Pharmacology
SN - 1751-2433
IS - 5
ER -